BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 9
• 10
• 11
• 12
• 13
• 14
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24

• Press Releases

  First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis

  August 24, 2026

   · 

  10 min read
• Press Releases

  NRG Therapeutics Presents Data on Lead Clinical Asset NRG5051 Confirming Novel Disease-Modifying Approach to ALS

  August 24, 2026

   · 

  3 min read
• Press Releases

  Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization

  August 24, 2026

   · 

  3 min read
• Press Releases

  Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study

  August 24, 2026

   · 

  11 min read
• 

  Pipeline

  Boehringer Ingelheim suspends early study for pill candidate after ‘safety event’

  Not much is known about Boehringer Ingelheim’s drug candidate, dubbed BI 3031185, though the asset has completed at least two other Phase 1 studies this year.

  August 24, 2026

   · 

  1 min read

   · 

  Tristan Manalac
• 

  Vaccines

  Kennedy questions vaccination guidelines following Trump’s order to break up MMR

  The current classifications of vaccine recommendations could imply that not all shots require the consent of patients or their parents, according to Health Secretary Robert F. Kennedy Jr.

  August 24, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors

  August 24, 2026

   · 

  7 min read
• Press Releases

  European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status

  August 24, 2026

   · 

  18 min read
• Press Releases

  Kraig Biocraft Laboratories Boosts Spider Silk Output More Than 30% During the Most Technically Challenging Season of the Year

  August 24, 2026

   · 

  5 min read
• Press Releases

  Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer

  August 24, 2026

   · 

  8 min read